Global E-Health Forum - Hamburg 2010

25-26 October 2010, Hamburg, Germany.
The Global E-Health Forum has been conceived to create a unique opportunity to discuss potential solutions in patient-centric health management. The past three Baltic Conferences on E-Health (2007-2009) have generated considerable interest in countries far beyond the Baltic Sea Region. The reason is simple: Healthcare systems all over the world are facing very similar challenges. Demographic shifts, increased burden of chronic diseases and expensive treatments as well as the impact of globalization - to mention some of the most important ones.

Therefore, organisers of Baltic Conference on E-Health have decided to found the "Global E-Health Forum". The Global E-Health Forum will replace the Baltic Conference on E-Health and is scheduled for following dates:

Global E-Health Forum - Hamburg 2010
25-26 October 2010.

Hosts of Global E-Health Forum 2010 are the European Health Telematics Association (EHTEL), the Hamburg Chamber of Commerce and IBM in cooperation with Asklepios.

Program Outline

  • October 25, 2010
    At the Hamburg Chamber of Commerce, you may expect presentations of keynote speakers from different continents, breakout sessions (workshops and as well as discussion forums) and an accompanying exhibition of solution providers. The first day will end with a reception in the U.S. Consulate General ("the little White House at the lake Alster").
  • October 26, 2010
    The program at Asklepios clinics will offer presentations, guided tours and show cases of solution providers and a panel discussion.

If you are interested in the sponsorship opportunities (platinum sponsor, premium sponsor and sponsor/workshop) or in exhibiting at the Global E-Health Forum on October 25 in the Hamburg Chamber of Commerce, please explore:

Register now to benefit from early bird fee of Euro 299 incl. VAT. Regular fee will be Euro 399 incl. VAT. The fee includes the admission to all conference sessions, lunches, coffee breaks and the evening reception on October 25.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...